[1]雷 玲,闵 珺,刘 锋,等.黄芪对肝纤维化大鼠肝损伤保护作用及机制研究*[J].陕西中医,2020,(9):1192-1196.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.004]
　LEI Ling,MIN Jun,LIU Feng,et al.Study on protective effects and mechanism of astragalus on hepatic injury of rats with hepatic fibrosis[J].,2020,(9):1192-1196.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.004]
点击复制

黄芪对肝纤维化大鼠肝损伤保护作用及机制研究*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年9期
页码:
1192-1196
栏目:
基础研究
出版日期:
2020-09-05

文章信息/Info

Title:
Study on protective effects and mechanism of astragalus on hepatic injury of rats with hepatic fibrosis
作者:
雷 玲1; 闵 珺1; 刘 锋2; 肖秀清3; 杜 凡1
1.南昌大学第三附属医院(南昌 330008); 2.南昌市青山湖区食品药品监督管理局(南昌 330029); 3.中山大学附属第三医院(广州 510630)
Author(s):
LEI Ling; MIN Jun; LIU Feng; et al.
The Third Affiliated Hospital of Nanchang University(Nanchang 330008)
关键词:
黄芪;  肝纤维化;  p38丝裂原活化蛋白激酶;  MAPK激酶-3;  转录激活因子-2
Keywords:
Astragalus;  Hepatic fibrosis;  p38 mitogen-actived protein kinases;  MAPK Kinase 3;  Activating transcription factor 2
分类号:
R575.2
DOI:
DOI:10.3969/j.issn.1000-7369.2020.09.004
文献标志码:
A
摘要:
目的:研究黄芪对肝纤维化大鼠肝损伤的保护作用及相关机制。方法:将SD大鼠随机分为正常对照组、肝纤维化模型组、黄芪后处理组和阳性对照组,检测各组大鼠血清中ALT、AST活性和TBIL水平变化; 逆转录-聚合酶链反应检测各组大鼠肝脏组织5种主要致纤维化因子p38MAPK、TGF -β1、α-SMA、CTGF和Collegen Ⅳ mRNA表达水平; 免疫印迹法检测p38MAPK信号通路上下游蛋白MKK3和ATF-2的表达变化。结果:与肝纤维化模型组比较,黄芪后处理组大鼠血清中ALT、AST和TBIL水平明显降低(P<0.05),肝纤维病理变化明显减轻,p38MAPK、MKK3和ATF-2蛋白表达量均降低(P<0.05)。结论:黄芪通过p38MAPK信号通路对实验性肝纤维化大鼠肝损伤具有效的保护作用。
Abstract:
Objective:To study the protective effect of astragalus on liver injury in rats with liver fibrosis and its mechanism.Methods:SD rats were randomly divided into normal control group,liver fibrosis model group,astragalus post-treatment group and positive control group.Serum ALT,AST and TBIL levels in each group were detected.Five main fibrogenic factors:p38MAPK,TGF-β1、α-SMA,CTGF and Collegen Ⅳ mRNA expression in rat liver tissue between groups were detected by RT-PCR.Western blotting was used to detect the expression changes of MKK3 and ATF-2 proteins in the upstream and downstream p38MAPK signaling pathway.Results:Compared with the liver fibrosis model group,the serum levels of ALT,AST and TBIL in the astragalus post-treatment group were significantly reduced(P<0.05).The pathological changes of liver fibers were significantly reduced,and the protein expressions of p38MAPK,MKK3 and ATF-2 were significantly reduced(P<0.05).Conclusion:Astragalus has an effective protective effect on liver injury in rats with experimental liver fibrosis through the p38MAPK signaling pathway.

参考文献/References:

[1] 武彦芳.男性酒精性肝硬化患者脂联素、抵抗素水平与肝纤维化相关性研究[J].陕西医学杂志,2016,45(7):840-841.
[2] 吕艳艳,薛阳利,陶美花,等.黄芩苷联合干扰素α治疗乙型肝炎肝纤维化临床研究[J].陕西医学杂志,2018,47(5):643-645.
[3] 韩石蕊.芪参益气滴丸治疗肝纤维化疗效研究[J].陕西中医,2018,39(4):473-475.
[4] 李 敏,高 凯,王华林,等.柴胡皂苷d-黄芩苷配伍对CCl4诱导大鼠HSC的TLR4-NF-κB通路作用研究[J].陕西中医,2018,39(1):3-5.
[5] Tang LX,He RH,Yang G,et al.Asiatic acid inhibits liver fibrosis by blocking TGF-beta/smad signaling in vivo and in vitro[J].Plos One,2012,7(2):313-317.
[6] Christina AJ,Saraswathy GR,Robert SJ,et al.Inhibition of ccl4 induced liver fibrosis by piper longum linn[J].Phytomedicine,2006,13(3):196-198.
[7] Pratap A,Singh S,Mundra V,et al.Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling[J].Journal of Drug Targeting,2012,20(9):770-782.
[8] Zhang LJ,Schuppan D.Traditional Chinese medicine for fibrotic liver disease:hope and hype[J].Journal of Hepatology,2014,61(1):166-168.
[9] 李 荣,李 蓉.苦参黄芪汤抗大鼠肝纤维化作用机制的研究[J].陕西中医,2011,32(12):1674-1676.
[10] Goorden SM,Buffart TE,Bakker A,et al.Liver disorders in adults:ALT and AST[J].Nederlands Tijdschrift Voor Geneeskunde,2013,157(43):644-649.
[11] 高风琴,刘 瑞,董 璐,等.养血柔肝汤治疗慢性乙型肝炎肝纤维化临床研究[J].陕西中医,2017,38(11):1564-1566.
[12] 徐学刚,黄 毓,黄玉娟.益气活血解毒方治疗慢性病毒性乙型肝炎肝纤维化的临床研究[J].陕西中医,2015,36(11):1450-1452.
[13] 郝建梅,袁 超,杨 震.肝纤维化的中医病名探析[J].陕西中医,2013,34(7):867.
[14] 杨 祥,开 钧,王志敏,等.细胞焦亡在慢性肝脏疾病中作用的研究进展[J].中国药理学通报,2018,34(12):1638-1642.
[15] 李政通,李 俊,黄 成,等.CCl4诱导的大鼠肝纤维化模型肝纤维化逆转与MAPK信号通路的研究[J].中国药理学通报,2011,27(6):809-814.

相似文献/References:

[1]王吉利,赵艳龙△.黄芪多糖含量的相关种植因素研究[J].陕西中医,2019,(12):1803.
　WANG Jili,ZHAO Yanlong..Analysis of planting related factors affecting polysaccharide content of Astragalus[J].,2019,(9):1803.
[2]张瑞华,张静文,刘 玲,等.黄芪及其有效组分药理作用与临床应用现状[J].陕西中医,2021,(8):1138.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.037]
　ZHANG Ruihua,ZHANG Jingwen,LIU Ling,et al.The pharmacological effects and current situation of clinical application of Astragalus and its effective components[J].,2021,(9):1138.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.037]
[3]蒋淑莲,谭善忠,文 剑.柴芍六君汤治疗慢性乙型肝炎肝纤维化疗效及对患者血清Treg/Th17的影响[J].陕西中医,2021,(9):1229.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.020]
　JIANG Shulian,TAN Shanzhong,WEN Jian.Therapeutic effect of Chaishao Liujun decoction on hepatic fibrosis in chronic hepatitis B and effect on serum Treg/Th17[J].,2021,(9):1229.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.020]
[4]蔡 菁,葛亚强,许丽娟,等.蒿属香豆素对MCD饮食诱导的非酒精性脂肪性肝纤维化小鼠保护性作用的研究[J].陕西中医,2021,(11):1511.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.004]
　CAI Jing,GE Yaqiang,XU Lijuan,et al.Protective effect of scoparone on MCD diet induced liver fibrosis in mice[J].,2021,(9):1511.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.004]
[5]吴必建,章一凡.猪苓汤加味联合多烯磷脂酰胆碱治疗早期肝硬化疗效研究[J].陕西中医,2021,(12):1706.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.013]
[6]苟 芳,张红军,王 洁,等.黄连解毒汤通过抑制TGF-β信号通路减轻2型糖尿病大鼠肝脂肪变性和纤维化研究[J].陕西中医,2022,(2):170.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.007]
　GOU Fang,ZHANG Hongjun,WANG Jie,et al.Huanglian Jiedu decoction alleviates hepatic steatosis and fibrosis in type 2 diabetic rats through activation of TGF - β signaling pathway[J].,2022,(9):170.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.007]
[7]孙素红,周晓玲,李泽鹏,等.柴胡当归散加减联合穴位注射丹参注射液治疗乙肝肝纤维化临床观察[J].陕西中医,2024,(4):477.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.009]
　SUN Suhong,ZHOU Xiaoling,LI Zepeng,et al.Clinical observation on the treatment of liver fibrosis in hepatitis B with modified Chaihu Danggui powder combined with acupoint injection of Danshen injection[J].,2024,(9):477.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.009]
[8]谢 旭,李国焕,贾文燕,等.参芪软肝汤配合抗病毒药物治疗肝硬化临床研究[J].陕西中医,2024,(6):771.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.010]
　XIE Xu,LI Guohuan,JIA Wenyan,et al.Shenqi Ruangan decoction combined with antiviral drugs in the treatment of liver cirrhosis[J].,2024,(9):771.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.010]
[9]魏涛华,杨文明,宋宇琪,等.名中医杨文明治疗Wilson病患者肝纤维化之肝豆扶木汤理法方药体系探析[J].陕西中医,2025,46(4):527.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.020]

备注/Memo

备注/Memo:
*江西省卫生健康委员会科技计划项目(20184004)
更新日期/Last Update: 2020-09-08